Application of entacapone, pharmaceutical composition, pharmaceutical preparation and application of entacapone

Entacapone, as an OGG1 inhibitor combined with methotrexate, solves the drug resistance and side effects in the treatment of rheumatoid arthritis, and provides an effective and safe treatment plan to reduce A The dosage and side effects of amothoprin improve the therapeutic effect.

CN118924731APending Publication Date: 2024-11-12UNIV OF MACAU +2
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310523940.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing rheumatoid arthritis treatment drugs such as methotrexate are prone to drug resistance and side effects during long-term use, and lack effective anti-inflammatory drug options.

Method used

As an OGG1 inhibitor, Entacapone reduces the transcriptional expression of inflammatory genes by inhibiting the activity of OGG1 enzyme, and combines methotrexate to form a drug combination, which significantly reduces the dosage and side effects of methotrexate and improves the therapeutic effect.

Benefits of technology

The composition of Entacapone and methotrexate can effectively treat rheumatoid arthritis, significantly reduce the dosage and side effects of methotrexate, improve the treatment effect, reduce the burden on patients, and has low toxicity and low cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924731A_ABST
    Figure CN118924731A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of new application of drugs, in particular to application of entacapone, a pharmaceutical composition, a pharmaceutical preparation and application of the entacapone. The invention discloses application of entacapone or pharmaceutically acceptable salt thereof in preparation of an OGG1 inhibitor. The embodiment of the invention provides a new application of entacapone, the entacapone can be used as an OGG1 inhibitor to inhibit OGG1, then the transcription expression of a pro-inflammatory gene can be inhibited, inflammation can be reduced, the effect of treating inflammation can be achieved, and the original dosage of the entacapone is lower than the maximum recommended dosage for treating Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of new drug applications, and in particular to the application, pharmaceutical composition and pharmaceutical preparation of entacapone and the application thereof. Background Art

[0002] Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, abnormal synovial proliferation, and cartilage destruction. Progressive development can cause joint deformities and even disability, causing great physical and psychological trauma to patients and a huge economic burden to society. With the rapid economic development, the prevalence of RA has been on a steady upward trend.

[0003] Entacapone (hereinafter referred to as ENT) is an FDA-approved drug. It is a specific peripheral catecholamine-O-methyltransferase (COMT) inhibitor clinically. It can effectively inhibit the 3-O-methylation of levodopa and enhance the bioavailability of levodopa in the central nervous system, thereby improving the efficacy of levodopa, reducing the dosage and the number of medications, and improving the motor fluctuations caused by long-term use of levodopa. It has been widely used in the adjuvant treatment of Parkinson's disease (PD). In clinical treatment, the maximum recommended dose of entacapone (ENT) for adults is 2g / day (200mg / time, 10 times / day). There have been no widespread reports of hepatotoxicity. Diarrhea is its most important non-dopaminergic-related adverse reaction. It is clinically believed that the use of entacapone (ENT) is safer and well tolerated. However, there is no record in the prior art that entacapone has anti-inflammatory effects.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The purpose of the present invention is to provide the application, pharmaceutical composition and pharmaceutical preparation of entacapone and the application thereof. The embodiments of the present invention provide new applications of entacapone, expand the application scope of entacapone, and also provide more choices for anti-inflammatory drugs, especially drugs for treating arthritis.

[0006] The present invention is achieved in that:

[0007] In a first aspect, the present invention provides a use of entacapone or a pharmaceutically acceptable salt thereof in the preparation of an OGG1 inhibitor.

[0008] In a second aspect, the present invention provides a use of entacapone or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating inflammation.

[0009] In a third aspect, the present invention provides a use of an OGG1 inhibitor in the preparation of a medicament for treating arthritis.

[0010] In an alternative embodiment, the arthritis is rheumatoid arthritis;

[0011] Preferably, the OGG1 inhibitor is entacapone or a pharmaceutically acceptable salt thereof.

[0012] In a fourth aspect, the present invention provides a use of an OGG1 inhibitor in the preparation of a drug for repairing bone damage.

[0013] In an alternative embodiment, the bone destruction is bone erosion;

[0014] Preferably, the OGG1 inhibitor is entacapone or a pharmaceutically acceptable salt thereof.

[0015] In a fifth aspect, the present invention provides a pharmaceutical composition, the raw materials of which include methotrexate or a pharmaceutically acceptable salt thereof and an OGG1 inhibitor.

[0016] In an optional embodiment, the mass ratio of the methotrexate to the OGG1 inhibitor is 1:80-85;

[0017] Preferably, the OGG1 inhibitor is entacapone or a pharmaceutically acceptable salt thereof.

[0018] In a sixth aspect, the present invention provides a pharmaceutical preparation comprising the pharmaceutical composition described in the aforementioned embodiment.

[0019] In an optional embodiment, the pharmaceutical preparation is a pharmaceutical package;

[0020] Preferably, when the pharmaceutical preparation is a drug package, the drug package comprises a first component package and a second component package, the first component package comprises methotrexate or a pharmaceutically acceptable salt thereof, and the second component package comprises an OGG1 inhibitor;

[0021] Preferably, the pharmaceutical preparation includes granular preparation, powder preparation, embolic preparation and liquid preparation;

[0022] Preferably, the pharmaceutical preparation further comprises a pharmaceutically acceptable excipient.

[0023] In a seventh aspect, the present invention provides a use of the pharmaceutical composition described in the aforementioned embodiment or the pharmaceutical preparation described in the aforementioned embodiment in the preparation of a drug for treating arthritis or a drug for repairing bone damage;

[0024] Preferably, the arthritis comprises rheumatoid arthritis;

[0025] Preferably, the bone destruction is bone erosion.

[0026] The present invention has the following beneficial effects: (1) The embodiment of the present invention provides a new application of entacapone, which can be used as an OGG1 inhibitor to inhibit OGG1, thereby inhibiting the transcriptional expression of pro-inflammatory genes, thereby reducing inflammation, and can have the effect of treating inflammation, and its usage amount is lower than the maximum recommended dose for treating Parkinson's disease. (2) Entacapone can be used in combination with methotrexate to treat arthritis, especially rheumatoid arthritis. In the process of combining with methotrexate, the dosage of methotrexate can be significantly reduced, thereby reducing its side effects. That is to say, the combination formed by methotrexate and entacapone has excellent therapeutic effect on arthritis, low toxic side effects, low treatment cost, and reduces the burden on patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0028] Figure 1 A graph showing the inhibitory activity of entacapone (ENT) provided in Experimental Example 1 of the present invention on the repair of oxidized guanine base (8-oxoG) by OGG1 protein in vitro;

[0029] Figure 2 A graph showing the binding affinity of entacapone (ENT) to the recombinant active protein OGG1 provided in Experimental Example 2 of the present invention;

[0030] Figure 3 A graph showing the results of the interaction between entacapone (ENT) and OGG1 and NF-κB protein provided in Experimental Example 3 of the present invention;

[0031] Figure 4 A graph showing the results of the interaction of entacapone (ENT) with promoters of various inflammatory inducing factors provided in Experimental Example 4 of the present invention;

[0032] Figure 5 A graph showing the results of the inhibitory effect of entacapone (ENT) combined with MTX on LPS-induced NF-κB transcription activity provided in Experimental Example 5 of the present invention;

[0033] Figure 6 A graph showing the results of the inhibitory effect of entacapone (ENT) combined with MTX on LPS-induced inflammatory factor mRNA provided in Experimental Example 6 of the present invention;

[0034] Figure 7A graph showing the results of the inhibitory effect of entacapone (ENT) combined with methotrexate on paw swelling in AIA rats provided in Experimental Example 7 of the present invention;

[0035] Figure 8 The results show that the combination of entacapone (ENT) and methotrexate provided in Experimental Example 8 of the present invention has an effect on Treg cells (CD4 + Foxp3 + T cell) differentiation results;

[0036] Fig. 9 A graph showing the results of the inhibitory effect of entacapone (ENT) combined with methotrexate on inflammatory factors in AIA rats provided in Experimental Example 9 of the present invention;

[0037] Fig.10 10 represents a representative CT image of the foot and ankle joint of an AIA rat provided in Experimental Example 10 of the present invention;

[0038] Fig.11 The graph shows the results of the bone protective effect of entacapone (ENT) combined with methotrexate on AIA rats provided in Experimental Example 10 of the present invention. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0040] 8-Oxoguanine DNA glycosylase 1 (hereinafter referred to as OGG1) is one of the main enzymes that repairs 7,8-dihydro-8-oxoguanine (8-oxoG) in DNA, and is a key regulator of inflammatory symptoms. Under oxidative stress, the enzymatic function of OGG1 is affected by cysteine ​​modification, and the OGG1-8-oxoG-DNA complex can promote the transcriptional expression of target pro-inflammatory genes through the NF-κB transcription mechanism. Therefore, by inhibiting OGG1, NF-κB transcription can be effectively inhibited, thereby promoting anti-inflammation. The embodiment of the present invention found that entacapone (hereinafter referred to as ENT) can regulate OGG1 activity, which can inhibit OGG1, and therefore, it can be used as an OGG1 inhibitor.

[0041] At the same time, the embodiments of the present invention also found that entacapone can inhibit the expression of multiple inflammatory factors, so it also has the effect of treating inflammation.

[0042] The present invention also found that entacapone, as an OGG1 inhibitor, has a therapeutic effect on arthritis, especially rheumatoid arthritis, and has a reversible repair effect on bone destruction. Therefore, it can also be used as a drug for treating arthritis and repairing bone destruction.

[0043] Further, methotrexate (full text also referred to as MTX) can control the development of rheumatoid arthritis disease well, but its treatment course is long, and many patients are reduced or unresponsive to MTX sensitivity as the treatment time increases, and develop drug resistance, resulting in poor MTX treatment effect. In addition, long-term use of methotrexate can cause side effects such as bone marrow suppression, gastrointestinal diseases, liver diseases, pneumonia, etc., which is also one of the reasons for limiting MTX long-term treatment. Therefore, although MTX has been used clinically in combination with other biological anti-rheumatic drugs (bDMARDs) for the treatment of RA, such as TNF-α inhibitors, how to develop a new drug combination to effectively improve the drug resistance and side effects of MTX for the treatment of RA is still a major challenge for the treatment of rheumatoid arthritis. And reducing the dosage is an effective strategy to alleviate the side effects of MTX treatment, but after reducing the dosage, the drug effect may also decline therewith, therefore, how to provide a new composition, both can reduce the dosage of methotrexate, and can ensure that the therapeutic effect of the composition is a problem that needs to be solved urgently.

[0044] The present invention embodiment found that when OGG1 inhibitor and MTX are used in combination, the dosage of MTX can be significantly reduced, and the side effects of MTX are well improved, that is, the formed composition has low toxicity and side effects, and the drug resistance to MTX is also improved. In particular, when entacapone is used as an OGG1 inhibitor and combined with MTX to form a composition, not only is the dosage of entacapone far lower than the equivalent dosage of the maximum recommended dose for adults relative to rats, but the dosage of MTX is also small. At the same time, the therapeutic effect is excellent, and a composition with low toxicity and few side effects can be obtained, which improves the side effects caused by long-term use of MTX, low sensitivity and drug resistance caused by methotrexate in the treatment of rheumatoid arthritis.

[0045] Specifically, the mass ratio of methotrexate to the OGG1 inhibitor in the pharmaceutical composition is 1:80-85, for example, any value between 1:80, 1:81, 1:82, 1:83, 1:84 and 1:85, etc.

[0046] Furthermore, the pharmaceutical composition can be prepared as a medicine with a certain dosage form, and when preparing as a pharmaceutical preparation, the methotrexate or a pharmaceutically acceptable salt thereof and the OGG1 inhibitor in the pharmaceutical composition can be mixed together and then prepared, or can be prepared separately and then taken together when taken.

[0047] Specifically, the pharmaceutical preparation can be a drug package, in which case the drug package includes a first component package and a second component package, the first component package includes methotrexate or a pharmaceutically acceptable salt thereof, and the second component package includes an OGG1 inhibitor; the first component package and the second component package can each contain pharmaceutically acceptable excipients, such as a solubilizer and a disintegrant, etc., or the excipients can be provided separately as a third component package, and then when taking the pharmaceutical preparation, the two component packages can be mixed and taken. The above-mentioned drug package or component package can be a granular preparation, a powder preparation, an embolic preparation, a liquid preparation, or other known preparations.

[0048] The pharmaceutical preparation may also be a preparation formed by mixing methotrexate or a pharmaceutically acceptable salt thereof with an OGG1 inhibitor, and the preparation may be a granular preparation, a powder preparation, an embolic preparation, a liquid preparation or other known preparations. In this case, the pharmaceutical preparation may also include pharmaceutically acceptable excipients, such as carriers, solubilizers, disintegrants and fillers.

[0049] The pharmaceutical composition and pharmaceutical preparation provided by the embodiments of the present invention have excellent therapeutic effects on arthritis, especially rheumatoid arthritis, and have low toxic and side effects.

[0050] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0051] Example 1

[0052] An embodiment of the present invention provides a drug package, which includes a first component package and a second component package, the first component package includes 30 mg of entacapone, and the second component package includes 0.357 mg of methotrexate.

[0053] Example 2

[0054] An embodiment of the present invention provides a pharmaceutical composition comprising 285 mg of entacapone and 3.57 mg of methotrexate.

[0055] Example 3

[0056] An embodiment of the present invention provides a pharmaceutical composition comprising 340 mg of entacapone and 4 mg of methotrexate.

[0057] Experimental example

[0058] In a specific embodiment of the present invention, the modeling agent used is complete Freund's adjuvant (mixed by heat-killed tuberculosis bacteria and liquid mineral oil), tuberculosis bacteria (M.TUBERCULOSIS DES.H37RA) is purchased from DIFCO, USA, mineral oil (MINERAL OIL) is purchased from Sigma, USA, methotrexate is methotrexate tablets (national medicine standard H31020644) produced by Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd., and entacapone is purchased from Shanghai Hanxiang Biotechnology Co., Ltd. (purity>98%). Foot swelling is measured on an Ugo Basile foot volume meter, bone and joint micro CT is scanned on SkyScan1176 (Bruker, Belgium), analyzed using NRecon software (Bruker-micro CT, Belgium), real-time fluorescence quantitative PCR is analyzed on a Life Technologies ViiA-7 instrument, and the proportion of Treg lymphocytes is analyzed using a BD FACSAria III four-way flow cytometer.

[0059] Experimental Example 1

[0060] Effect of Entacapone (ENT) on the repair of oxidized guanine base (8-oxoG) by OGG1 protein in vitro

[0061] A screening method for OGG1 regulators was established based on TRES (time-resolved emission spectroscopy), as follows: a DNA strand containing a G-quadruplex-forming sequence (OS1, 5'-TG4AG3TG4AG3TG4AAG2G*CACTGCGTCGAC2TG-3', * indicates 8-oxoG) was initially heated at 90°C for 8 min and then cooled to room temperature at 0.1°C / s to form a double-stranded substrate (OS1 / 2) and stored at -20°C. A volume of 250uL containing a final concentration of 100nM double-stranded substrate was incubated at 37°C for 30 minutes with 8nM OGG1, 20nM APE1, buffer (25mM Tris-HCl pH 8.0, 15mM NaCl, 2mM MgCl2, 0.5mM DTT) and different doses (0, 0.03, 0.1, 0.3, 1, 3, 10 and 30μM) of ENT. The mixture was cooled and then diluted to a final volume of 500μL using Tris buffer (50mM Tris, 20mM KCl, 150mM NH4OAc, pH7.0). The probe was added to a final concentration of 0.5μM. A delay time of 500ns was used on a Fluorolog-3 spectrophotometer to monitor the luminescence emission intensity of 450-700nm after exciting the sample at 355nm.

[0062] Results Figure 1 ,according to Figure 1 It can be seen that ENT showed a dose-dependent inhibitory effect on OGG1 activity, IC 50 It is 9.33μM.

[0063] Experimental Example 2

[0064] Binding affinity of entacapone (ENT) to recombinant active protein OGG1

[0065] The binding affinity of the inhibitor ENT to the recombinant active protein OGG1 was measured by biolayer interferometry on OctetRed 96 (Fortebio). Specifically, the Ni-NTA biosensor was loaded with His-tagged OGG1 in BLI kinetic buffer (PBS buffer containing 0.02% Tween 20 and 0.1% BSA), washed in the same buffer and transferred to a 96-well all-black ELISA plate containing ENT. The Ni-NTA biosensor tip coated with the His-tagged protein complex was immersed in increasing concentrations of ENT for 300 seconds and then separated in the well containing the buffer for another 300 seconds. The negative control of the Ni-NTA biosensor with BLI kinetic buffer was subtracted from the sample response of the Ni-NTA biosensor loaded with OGG1. The equilibrium dissociation constant (Kd) value of the 1:1 interaction was calculated from the steady-state fit. Kd and the associated standard error were calculated using Octet analysis software.

[0066] The results are as follows Figure 2 As shown, the results showed that ENT bound to the recombinant His-tagged OGG1 protein complex with a Kd value of 3.80 μM (steady-state fitting), indicating that the OGG1 inhibitor ENT had a good binding affinity to the recombinant active protein OGG1.

[0067] Experimental Example 3

[0068] Effect of entacapone (ENT) as an OGG1 inhibitor on the interaction between OGG1 and NF-κB protein

[0069] Since OGG1 can regulate the expression of proinflammatory genes through direct interaction with NF-κB and chromatin, this experimental example performed a co-immunoprecipitation (Co-IP) experiment to explore whether ENT can affect the interaction between OGG1 and NF-κB. Specifically, RAFLS cells were treated with 0.1% DMSO, 5μM ENT or 5μM TH5487 (OGG1 inhibitor positive control (refer to Visnes, T., et al., Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation. Science, 2018. 362 (6416): p. 834-839)) for 1 hour, and then treated with 100ng / mL LPS for 1h. 100μg of collected cell lysate was incubated with 10μg NF-κB subunit p50 antibody in 500μL cell lysis buffer at 4°C overnight. The mixture was then added to a 1.5 mL microcentrifuge tube containing pre-washed magnetic beads and incubated with mixing at room temperature for 1 h. The immunoprecipitated proteins were subjected to SDS-PAGE and then immunoblotted with anti-OGG1 and anti-p50 antibodies.

[0070] The results are as follows Figure 3 As shown, according to Figure 3 It can be seen that the amount of OGG1 co-precipitated with NF-κB subunit p50 was reduced after treatment with ENT or TH5487. The results showed that ENT could block the interaction between OGG1 and NF-κB, indicating that ENT can act as an OGG1 inhibitor.

[0071] Experimental Example 4

[0072] Effect of entacapone (ENT) on the interaction between OGG1 and promoters of multiple inflammatory factors

[0073] Chromatin immunoprecipitation (ChIP) assay was used to evaluate the effect of ENT on the binding of OGG1 to chromatin. Specifically, RAFLS cells were treated with 0.1% DMSO, 5μM ENT or 5μM TH5487 for 1 hour and then treated with 100ng / mL LPS for 1 hour. Cross-linking was performed using a cross-linking solution (1.1% formaldehyde, 5mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.3, 10mM NaCl, 100μM ethylenediaminetetraacetic acid (EDTA), 50μM ethylene glycol tetraacetic acid (EGTA), followed by washing twice with phosphate-buffered saline (PBS). The cells were scraped and frozen in liquid nitrogen, and OGG1 antibody (1:50) was used to capture DNA fragments. The recovered DNA was resuspended in TE buffer for PCR amplification and real-time qPCR (ViiA TM 7System, Life Technologies) to analyze the recovered DNA.

[0074] The results are as follows Figure 4 As shown in the figure, ChIP analysis of CXCL1 promoter showed that 5 μM ENT or TH5487 reduced LPS-induced OGG1 recruitment to chromatin, and a similar pattern was observed on the TNF promoter. The results showed that ENT can not only block OGG1-NF-κB protein-protein interaction, but also inhibit the interaction between OGG1 protein and chromatin, reducing the effects of multiple inflammatory induction factors.

[0075] Experimental Example 5

[0076] In vitro study of the effect of entacapone (ENT) combined with low-dose MTX on LPS-induced NF-κB transcriptional activity

[0077] To evaluate the effect of MTX and ENT drug combination on NF-κB directional transcription, we used a dual luciferase assay to measure NF-κB transcriptional activity. Specifically, RAFLS cells were mixed with NF-κB responsive luciferase reporter plasmid and Renilla luciferase control reporter plasmid using TurboFect transfection reagent and transfected for 32 hours. The cells were then treated with 0.1% DMSO, 5μMENT, 5μM MTX and ENT combined with MTX drugs for 1 hour and treated with 10ng / mL TNF-α for 6 hours before lysis. Luciferase activity will be measured using a spectrophotometer (Spectra-max M5, Molecular Devices, USA). The results will be standardized with the activity results of Renilla luciferase.

[0078] The results are as follows Figure 5As shown, the results of NF-κB dual luciferase assay showed that the NF-κB luciferase transcription activity in the MTX and ENT combined treatment group was significantly reduced compared with the MTX (reduced by about 8 times) or ENT (reduced by about 5 times) single treatment groups, indicating that ENT can enhance the inhibitory ability of MTX on NF-κB transcription activity, thereby reducing the inflammatory response caused by the inflammatory transcription factor NF-κB.

[0079] Experimental Example 6

[0080] In vitro study of the effect of entacapone (ENT) combined with low-dose MTX on LPS-induced inflammation

[0081] Specifically, fibroblast-like synoviocytes (RAFLS) of RA patients were treated with 0.1% DMSO, 5μMENT, 5μM MTX and ENT combined with MTX for 1 hour, and then treated with 100ng / mL LPS for 1 hour. Total RNA of cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from 1μg RNA using SuperScript III first-strand synthesis system (Invitrogen). Quantitative RT-PCR was performed on Step-One plus real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA) using SYBR green PCR Master Mix.

[0082] The results are as follows Figure 6 As shown in the data, the mRNA levels of TNF-α, IL-6, CXCL1, CXCL10, CCL-2, and CCL-20 increased significantly after LPS stimulation. MTX or ENT could reduce the expression of these inflammatory factors to a certain extent, but the expression of pro-inflammatory genes in the MTX and ENT combined treatment group was reduced compared with the MTX or ENT alone treatment group.

[0083] Experimental Example 7

[0084] Effect of entacapone (ENT) combined with methotrexate on alleviating foot swelling in rats with AIA arthritis

[0085] SPF male SD rats weighing 110-130 g were obtained from the Chinese University of Hong Kong (all animal care and experiments were approved by the Animal Ethics Committee of the Health Supervision Bureau of the Macao Special Administrative Region of China, and were conducted in accordance with the Guidelines for Institutional Animal Care and Use Committee of the Macau University of Science and Technology). Thirty rats were randomly divided into five groups (control group, AIA model group, MTX treatment group, ENT treatment group, and ENT+MTX treatment group). Except for the control group, the remaining animals were modeled and injected intradermally with 0.1 mL of complete Freund's adjuvant at the base of the tail. The control group was injected with an equal amount of normal saline in the same way as a control. After modeling, ENT was intraperitoneally injected at a dose of 30 mg / mL daily (the maximum recommended dose of 2 g / d for adults is converted to an equivalent dose of 210 mg / kg / d for rats, and the dose used in this example is much lower than the maximum recommended dose) for 27 consecutive days. MTX was administered by oral gavage every week at a dose of 2.5 mg / kg (the normal effective dose is 7.6 mg / kg). The ENT+MTX group was administered in combination with the above dose and administration method. The paw volume of the rats was measured every 3 days (measured using a limb swelling meter (Ugo Basile, Italy) and arthritis scores were performed.

[0086] The scoring criteria are shown in the following table.

[0087]

[0088] The results are as follows Figure 7 As shown in the data, compared with the healthy control group, the AIA model group developed obvious foot swelling from the 12th day, and the arthritis score increased significantly (P<0.01). The single use of MTX at a dose of 2.5 mg / kg and ENT at a dose of 30 mg / kg could not effectively inhibit the degree of foot swelling and arthritis score of AIA rats, but the combination of 2.5 mg / kg MTX and 30 mg / kg ENT could significantly reduce the foot swelling and arthritis score of AIA rats (P<0.01). The increased foot volume of rats in the combination group was equivalent to that of the control group, and the arthritis score was slightly higher than that of the control group.

[0089] Experimental Example 8

[0090] Effect of Entacapone (ENT) combined with MTX on Treg cell differentiation

[0091] After the 27th day, the rats in Example 7 were dissected, spleen tissue was taken, ground through a 200-mesh sieve, and cells were rinsed with phosphate buffer. The collected spleen cells were stained with anti-CD45 antibody coupled with APC-Cy7, anti-CD3 antibody coupled with FITC, and anti-CD4 antibody coupled with PerCP-Cy5-5. After staining, the nuclei were broken with a fixed nuclear membrane solution, and the cells were washed with a buffer solution and stained with an anti-Foxp3 antibody coupled with PE-A. The cells were analyzed using a BD FACSAria III four-way flow cytometer, and the relevant data were processed on FlowJo software.

[0092] Various subtypes of T cells have been shown to be involved in the pathological process of RA. In RA patients, the differentiation and function of Treg cells are usually suppressed. Treg cells can exert anti-inflammatory effects and regulate autoimmune tolerance by secreting IL-10 and TGF-β. Figure 8 As shown, compared with the control group, the CD4 + Foxp3 + T cells (Treg cells) were significantly reduced (P<0.001), 2.5mg / kg MTX could slightly increase the proportion of Treg cells, but the combination of ENT and MTX could significantly increase the proportion of Treg cells (P<0.001). The above results show that under RA conditions, the combination of ENT and MTX can promote Treg cell differentiation, increase the proportion of Treg, and achieve anti-arthritis effects.

[0093] Example 9

[0094] Effects of Entacapone (ENT) combined with MTX on inflammatory factors in peripheral blood mononuclear cells of AIA rats

[0095] On the 27th day, peripheral blood of rats in Example 7 was taken, a certain amount of red blood cell lysis solution was added, and the cells were centrifuged after being lysed on ice for 10 minutes. Total RNA of peripheral blood mononuclear cells was extracted using TRIzol (Invitrogen, USA), and 1 μg RNA was reversely transcribed into cDNA by Master Mix kit (Roche, Switzerland). Fluorescent dye FastStart Universal SYBR-Green Master Rox (Roche Diagnostics, Indianapolis, IN, USA) was combined with cDNA, and the RT-PCR mixture included 0.5 μL of total cDNA, 0.5 μL of forward primer and reverse primer, 10 μL of SYBR Master Mix reagent and 8.5 μL of sterile water, with a total volume of 20 μL. Real Time-PCR program (ViiA 7real-time PCRsystem, USA) was run, and the ΔΔCT method was used for data analysis and processing results. The expression of TNF-α, IL-1β, COX-2, IL-2, IL-8, and IL-17a was obtained by comparison with the internal reference.

[0096] The results are as follows Fig. 9 As shown in the results, the expression of the above six inflammatory factors was significantly upregulated in the AIA model group. Neither ENT nor MTX could completely inhibit their high expression after AIA modeling, but the combination of ENT and MTX significantly reduced the expression of TNF-α, IL-1β, COX-2, IL-2, IL-8, and IL-17a. The above results show that the combination of ENT and MTX can inhibit the expression of inflammatory factors and reduce inflammatory response.

[0097] Experimental Example 10

[0098] Effect of entacapone (ENT) combined with MTX on bone destruction in AIA rats

[0099] After 27 days, the rats in Example 7 were killed, and the left legs were fixed in 4% PFA, and microCT scans were performed on SkyScan 1176, and 3D reconstruction was performed using NRecon software to obtain CT scan images.

[0100] The results are as follows Fig.10 As shown in the figure, the bone of the control group was clear and intact, the metatarsal bones of the AIA group showed severe bone erosion, and some bone joints only retained part of the outline. Low-dose MTX could not significantly reduce bone destruction after modeling. The degree of bone erosion in the ENT group was lighter than that in the AIA group. The combination of ENT and MTX almost reversed the bone destruction caused by AIA modeling, and the appearance was comparable to that of the control group. This shows that the combination of ENT and MTX can repair bone destruction.

[0101] The calcaneal part was analyzed by microCT to calculate bone density, bone volume fraction, cortical bone density, trabecular number and total porosity. The microCT score was calculated based on the above five data.

[0102] The results are as follows Fig.11 As shown in the results, compared with the AIA model group, the combination of ENT and MTX can significantly improve the microCT score and reduce bone erosion (P<0.001). The above results show that the combination of ENT and MTX has a bone protective effect on AIA rats and significantly reduces bone destruction after modeling.

[0103] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of entacapone or a pharmaceutically acceptable salt thereof in the preparation of an OGG1 inhibitor.

2. Use of entacapone or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating inflammation.

3. Use of an OGG1 inhibitor in the preparation of a drug for treating arthritis; Preferably, the arthritis is rheumatoid arthritis; Preferably, the OGG1 inhibitor is entacapone or a pharmaceutically acceptable salt thereof.

4. Use of an OGG1 inhibitor in the preparation of a drug for repairing bone damage.

5. The use according to claim 4, characterized in that: The bone destruction is bone erosion; Preferably, the OGG1 inhibitor is entacapone or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition, characterized in that The raw materials include methotrexate or a pharmaceutically acceptable salt thereof and an OGG1 inhibitor.

7. The pharmaceutical composition according to claim 6, characterized in that The mass ratio of the methotrexate to the OGG1 inhibitor is 1:80-85; Preferably, the OGG1 inhibitor is entacapone or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical preparation, characterized in that It comprises the pharmaceutical composition according to claim 6 or 7.

9. The pharmaceutical preparation according to claim 8, characterized in that The pharmaceutical preparation is a pharmaceutical package; Preferably, when the pharmaceutical preparation is a drug package, the drug package comprises a first component package and a second component package, the first component package comprises methotrexate or a pharmaceutically acceptable salt thereof, and the second component package comprises an OGG1 inhibitor; Preferably, the pharmaceutical preparation includes granular preparation, powder preparation, embolic preparation and liquid preparation; Preferably, the pharmaceutical preparation further comprises a pharmaceutically acceptable excipient.

10. Use of the pharmaceutical composition according to claim 6 or 7 or the pharmaceutical preparation according to claim 8 or 9 in the preparation of a drug for treating arthritis or a drug for repairing bone damage; Preferably, the arthritis comprises rheumatoid arthritis; Preferably, the bone destruction is bone erosion.

Citation Information

Cited By

  • Application of OGG1 inhibitor in treatment of osteogenic differentiation disorder bone defect

    CN122005560A

  • Use of ogg1 inhibitors in the treatment of osteogenic differentiation disorder bone defects

    CN122005560B